Dare Bioscience (DARE) Cost of Revenue (2024 - 2026)
Dare Bioscience's (DARE) quarterly Cost of Revenue came in at $295799.0 in Q4 2025, up 3954.56% YoY from $7295.5 in Q4 2024, and up 3954.56% on a QoQ basis from -$7674.0 in Q4 2024.
Dare Bioscience (DARE) Cost of Revenue (2024 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 2 years of Cost of Revenue data on file, last reported at $295799.0 in Q4 2025.
- Quarterly Cost of Revenue rose 3954.56% year-over-year to $295799.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $295799.0 (changed N/A YoY) and the FY2025 annual result came in at $295799.0, changed N/A from the prior year.
- Cost of Revenue advanced to $295799.0 in Q4 2025, from -$7674.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $295799.0 in Q4 2025 to a low of -$7674.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dare Bioscience | 12.36 Mn | -256,055.23 | -132,343.00 | 319,889.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 319,889.00 |
| Jun 30, 2026 | 319,889.00 |
| Dec 31, 2025 | 295,799.00 |
| Dec 31, 2025 | 295,799.00 |
| Dec 31, 2024 | -7,674.00 |
| Dec 31, 2024 | -7,674.00 |
| Mar 31, 2024 | 7,674.00 |
| Mar 31, 2024 | 7,674.00 |